RankAlpha logo
Back to Rankings

AXSM

Axsome TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings bull read is that Axsome is now showing a rare mix for mid-cap biopharma: strong commercial growth, a fresh label expansion for AUVELITY, and management’s statement that current cash should fund operations into cash-flow positivity. The June 2026 Alzheimer’s agitation launch is the key operating lever if investors keep rewarding execution over near-term losses.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -2.3.
What can break
AUVELITY prescriptions were up 35% year over year but were described as consistent with 4Q25, which could imply a flatter near-term volume cadence until the new indication contributes.
Momentum
92
Value
41
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $224.00 · Bull $245.00 · Bear $185.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $223.65
Why
Momentum92 · Δ7d -2.3
Value41 · Δ7d +0.1
Sentiment48 · Δ7d +5.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
92
34% active weight
Current posture
7d trendFlat
Δ7d
-2.3
Δ21d
+2.6
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
48
33% active weight
Current posture
7d trendImproving
Δ7d
+5.6
Δ21d
+1.5
Why this grade

Composite grade B. Momentum 91.6 / Value 41.1 / Sentiment 48.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$11.85B
Beta
0.40
Shares Out
50.41M
P/E (TTM) · Derived
-63.8
P/S (TTM)
15.40
P/FCF (TTM) · Derived
-114.09
Rev YoY
+63.2%
EPS YoY
+29.6%
Gross Margin
+91.9%
Op Margin
-39.7%
Net Debt
-$130.28M
Current Ratio
1.57
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology